Blue background design

Pipeline

Aldeyra is a well-capitalized biotechnology company with a broad pipeline focused on immune-mediated and metabolic disease.

Reproxalap

Topical ocular administration
(Option agreement w/AbbVie)

Dry Eye Disease

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • NDA

Reproxalap

Topical ocular administration
(Option agreement w/AbbVie)

Allergic Conjunctivitis

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • NDA

ADX-629

Oral administration

Moderate Alcoholic Hepatitis

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • NDA

ADX-629

Oral administration

Sjögren-Larsson Syndrome

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • NDA

ADX-248

Oral administration

Atopic Dermatitis

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • NDA

ADX-743

Oral administration

Obesity/ Hypertriglyceridemia

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • NDA

ADX-631/ADX-246

Intravitreal injection

Dry Age-Related Macular Degeneration / Geographical Atrophy

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • NDA

ADX-2191*

Intravitreal injection

Retinitis Pigmentosa

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • NDA

ADX-2191*

Intravitreal injection

Primary Vitreoretinal Lymphoma

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • NDA
*U.S. FDA Orphan-Drug Designated
Don't delete this section - it contains the styling for the pipeline bars, but is invisible to visitors